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We conducted a systematic review and meta-analysis investigating the influence of AChEIs therapy 
on nutritional status and weight across observational and interventional studies. Two authors searched 
major electronic databases from inception until 10/14/2015 for longitudinal, open-label and 
randomized double blind placebo controlled (RCTs) studies of AChEIs in patients with dementia 
reporting nutritional status outcome data.  Out of 3,551 initial hits, 25 studies (12 open-label trials, 9 
RCTs and 4 longitudinal studies) including 10,792 patients with dementia were meta analyzed.  In 
longitudinal studies (median follow-up: 6 months), a significant cumulative incidence of weight loss 
between baseline and follow-up evaluation was observed (studies=2; 5%; 95%CI: 1-34%, p<0.0001; 
I2=95%). These findings were confirmed in open-label trials (6%; 95%CI: 4-7%, p<0.0001; I2=78%). 
In 9 RCTs (median follow-up: 5 months), those taking AChEIs more frequently experienced weight 
loss than participants taking placebo (OR=2.18; 95%CI: 1.50-3.17, p<0.0001; I2=29%). AChEIs 
therapy contributes to weight loss in patients with dementia, with a twofold increased risk observed 
in the meta-analysis of RCTs.  Clinicians should carefully consider the benefit and risk of prescribing 
AChEIs. Nutritional status should be routinely evaluated in patients with dementia treated with 
AChEIs. 




Malnutrition and cognitive decline are two considerable geriatric syndromes associated with 
considerable increased risk of premature mortality. Malnutrition and cognitive decline have been 
recently described in close relationship several mechanism could explain it.(1, 2) One is the 
occurrence of repeated actions and behavioral disorders due to episodic memory and impairment in 
attention resulting in increased energy loss in patients with dementia.(3) Another potential 
explanation is alteration of the sensation of smell and taste in addition to impaired swallowing 
function due to cholinergic deficits.(4, 5) Cognitive deterioration affects daily functional status and 
instrumental activities which result in disability, dependence and decreased oral intake.(6) Chewing 
problems and decreased appetite significantly affect food intake in patients with dementia.(7) In light 
of all these possible mechanisms, the risk of malnutrition can arise even within the prodromal period 
of dementia.(8) Also, nearly half of elderly patients with dementia in the population are at risk of 
malnutrition, and malnutrition in turn accelerates cognitive impairment, increases the incidence of 
behavioral disorders, and decreases functionality and quality of life in this population.(9, 10,11) As a 
consequence, a vicious cycle maintains malnutrition and cognitive deficit.  
Acetylcholinesterase inhibitors (AChEI) are the front-line pharmacotherapy in the treatment of mild 
to moderate dementia.(12) Although AChEI are not curative, they are able to stabilize memory and 
delay functional reduction.(13) However, it remains unclear how AChEI affect nutritional status (e.g. 
weight loss, malnutrition), a central factor that significantly influences disease progression.  It has 
been reported that AChEIs may accelerate weight loss by increasing cholinergic activity in the 
gastrointestinal system and causing nausea, vomiting and diarrhea, particularly in the beginning of 
treatment.(14) However, others have proposed that because AChEI improve the cognitive status, with 
good cognitive status being essential for the prevention of malnutrition, it is possible that an 
improvement of nutritional status could be observed.(15) Thus, there is currently no clear 
understanding of the impact of AChEI on nutritional parameters in older patients with dementia and 
to our knowledge no meta-analysis addressing this pertinent question exists.   
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Given the aforementioned, we conducted a systematic review and meta-analysis of observational and 
interventional studies to determine whether patients with dementia treated with AChEIs are at 
increased risk of poor nutritional status including weight loss, changes in body mass index and 






This systematic review was conducted according to the Strengthening the Reporting of Observational 
Studies in Epidemiology [STROBE] criteria and the recommendations in the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses [PRISMA] statement.(16, 17) 
2.1. Search strategy 
Two investigators (MS, CL) independently conducted an electronic literature search using PubMed 
and Scopus with no language restrictions, until 10/14/2015. In PubMed, the following controlled 
vocabulary terms and keywords were considered: ("donepezil"[All Fields] OR "galantamine"[All 
Fields] OR "rivastigmine"[All Fields] OR "cholinesterase inhibitors"[All Fields] OR 
"acetylcholinesterase inhibitors"[All Fields]) AND ("nutritional status"[mesh] OR "Nutrition 
Assessment"[mesh] OR "Nutrition Surveys"[mesh] OR "nutritional assessment"[All Fields] OR 
"body weight"[mesh] OR "weight"[All Fields] OR "body mass index"[All Fields] OR "BMI"[All 
Fields] OR "albumin"[All Fields] OR "albumins"[Mesh]). A similar search was run in Scopus. 
Reference lists of the articles included in the analysis and of others relevant to the topic were hand-
searched to identify additional, potentially relevant publications. Conference abstracts were also 
considered and Authors contacted for additional information if needed. Any inconsistencies were 
resolved by consensus with a third Author (EM).  
 
2.2. Study selection 
We only considered observational and interventional (open label and RCTs) studies that:(1) had a 
baseline and follow-up evaluation; (2) included patients with dementia diagnosed according 
standardized criteria (NINCDS-ARDRA: National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association or DSM: 
Diagnostic and Statistical Manual of Mental Disorders) (3) included at least one group taking AChEI 
including donepezil-DZP; galantamine-GAL; rivastigmine-RIV; (4) reported data on nutritional 
parameters in people taking AChEI (weight, body mass index, multidimensional tools for the 
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estimation of malnutrition, serum albumin levels). If the data about nutritional parameters were 
reported only at baseline, authors were contacted at least two times in one month for obtaining follow-
up information.  
Studies were excluded if: (1) did not include patients with dementia; (2) reported data on AChEI used 
for aims other than improving cognitive status (e.g. neostigmine, physostigmine etc.); (3) conducted 
in vitro and on animal models.  
The studies satisfying the inclusion/exclusion criteria were included and subsequently divided 
according their design in: a) longitudinal: repeated observations of the nutritional variables over a 
follow-up period without any pre-specified intervention; b) open-label: trials with a randomization 
phase and with a group taking no drugs or a group taking a different dose of the same drug; c) 
randomized double blind placebo controlled trials (RCTs): trials with a randomization phase and a 
group taking placebo.  
 
2.3.Data extraction 
Two authors (PS, GS) independently recorded data extracted from the selected studies in a 
standardized Microsoft Excel spreadsheet. Any disagreement was resolved by consensus with a third 
author (BS). The following information was extracted: i) characteristics of the study population (e.g. 
sample size, demographics, setting); ii) type of dementia (Alzheimer’s disease-AD; vascular 
dementia; others; mixed); iii) duration of dementia (years); iv) type of drug (donepezil-DZP; 
galantamine-GAL; rivastigmine-RIV) with the correspondent dosage; v) mean age and mean mini-
mental state examination (MMSE) (at baseline and at the follow-up where available); vi) duration of 
follow-up (months).   
 
2.4.Outcomes 
The primary outcomes were the changes between baseline and follow-up of the nutritional parameters 
(as continuous) including weight, BMI, multidimensional tools for assessing nutritional status (e.g. 
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mini-nutritional assessment, geriatric nutrition risk index or similar), and albumin. Since no studies 
included the changes of albumin between baseline and follow-up, this outcome was not included. We 
considered the number of those losing weight between follow-up and baseline as co-primary outcome 
too.  
 
2.5.Assessment of study quality 
For longitudinal and open-label trials without a comparison group, the Newcastle-Ottawa Scale 
(NOS) was used to assess study quality.(18) The NOS assigns a maximum of 9 points based on three 
quality parameters: selection, comparability, and outcome. The investigators solved any 
discrepancies by jointly re-assessing an article (PS, MS and GS). 
For RCTs, the quality of involved studies was evaluated using Jadad scale.(19) This scale includes 
randomization (0–2 points), blinding (0–2 points), and dropouts and withdrawals (0–1 point). The 
overall score of a study according to this scale ranges from 0-5, with higher scores indicating better 
quality.(20) Studies with Jadad scores≥3 were considered as high-quality. 
 
2.6.Statistical analysis 
The meta-analysis was performed using the Comprehensive Meta-Analysis 3.0.When combining 
studies, the random effects model was used to account for study heterogeneity.(21) In analyses 
regarding longitudinal and open-label trials, means and standard deviations (SD) of weight, BMI and 
mini-nutritional assessment (MNA) were analyzed assessing the differences between baseline and 
follow-up in order to calculate within groups standardized mean differences [SMD]. Event rate was 
used to assess the cumulative incidence of those with weight loss between baseline and follow-up 
evaluation. Within-study pooled estimates were also calculated as necessary (e.g. two groups taking 
different doses of the same drug). 
Regarding analyses including RCTs, only analyses about the number of participants losing weight 
were possible. The cumulative incidence of those losing weight in participants treated with AChEIs 
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and controls were calculated through odds ratios [OR]. All estimates were calculated together with 
95% confidence intervals [CI].  
Study heterogeneity was measured using the chi-squared and I-squared statistics, assuming that a 
p≤0.05 for the former and a value ≥50% for the latter indicated a significant heterogeneity.(22) In 
pre-planned analysis, we conducted a meta-regression analysis to see whether some variables could 
affect results about weight loss, namely continent in which the study was conducted (North America, 
Europe and Asia, multicontinent), type of drug (DZP, GAL, RIV, all drugs together), type of dementia 
(AD, other), follow-up duration and quality. Follow-up duration was categorized according with the 
median of the studies included (5 months for open-label; 6 for RCTs). For open-label studies, low 
quality was defined as eNOS<5 and high as eNOS>5; for RCTs low quality was defined as a Jadad’s 
score<3 points; high as > 3 points.(17, 20) 
Publication bias was assessed by visually inspecting funnel plots and using the Begg-Mazumdar 
Kendall tau and the Egger bias test.  Then, to account for publication bias, we used the trim-and-fill 
method, based on the assumption that the effect sizes of all the studies are normally distributed around 
the center of a funnel plot; in the event of asymmetries, it adjusts for the potential effect of 














The search identified 3,551 non duplicated potentially eligible studies. After excluding 3,464 papers 
at the titles and abstract review, 87 full-text articles were examined and 25 studies (12 open-label 
trials, 9 RCTs and 4 longitudinal studies) were finally included in systematic-review and meta-
analysis (See Supplementary Figure 1).  
 
3.1.Study and patient characteristics 
Study and patient characteristics are summarized in Supplementary Tables 1-3. Altogether the 25 
studies analyzed, represented a total of 10,792 patients with dementia, the majority of whom were 
women (6,741; 62.5%). Most studies were conducted in North America (14 studies: 8 open-label and 
6 RCTs), followed by Europe (8 studies: 3 longitudinal, 3 open-label and 1 RCT), Asia (2 studies: 1 
longitudinal and 1 open-label) and across different continents (2 studies: 1 open-label and 1 RCT) 
(Supplementary Tables 1-3). Twenty-one studies were conducted among community-dwelling 
participants, 2 among outpatients, 2 among inpatients and 1 in nursing home setting. The majority of 
the studies included only patients with Alzheimer’s disease (22 studies; 2 longitudinal, 11 open-label 
and 8 RCTs) mainly diagnosed with the criteria proposed by the National Institute of Neurological 
and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders 
Association (16 studies) (Supplementary Tables 1-3). 
 
3.2.Meta-analysis results 
3.2.1. Longitudinal studies reporting on nutritional parameters  
The four longitudinal studies included 751 subjects, mainly women (59.9%) and with a mean age of 
76.4±6.5 years.(15,25-27) Two studies used GAL, 1 RIV and 1 all AChEIs together. After a median 
follow-up period of 6 months, the mean MMSE score (baseline: 20.1±4.3) did not significantly 
improve at follow-up (p=0.09, paired T-test). The quality of the studies seems to be high as shown in 
the Supplementary Tables 1 and 4.  
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Regarding nutritional parameters, two studies reported a significant cumulative incidence of those 
with weight loss between baseline and follow-up evaluation (5%; 95%CI: 1-34%, p<0.0001; I2=95%) 
(Table 1).(15,26) On the contrary, no significant variations in body weight, BMI, or MNA were 
reported in one study.(15) 
It was not possible to assess publication bias due to the limited number of the studies included for 
each outcome.    
 
3.2.2. Open-label trials reporting on nutritional parameters  
The 12 open-label trials followed 5,730 patients with dementia, with a mean age of 76.0±7.0 years 
and mainly women for a median of 6 months (Supplementary Table 2).(28-39) The mean duration 
of the disease was 4.2±3.1 years. Seven studies used RIV, 5 DZP and 1 all the AChEI together. The 
mean baseline MMSE was of 16.4±3.7, while the comparison with the follow-up values was not 
possible due to limited data available for this outcome (8 studies did not report the MMSE value at 
the follow-up, 4 as a change and one as absolute value). The quality of the studies included suggested 
a high risk of bias as shown by the median eNOS score (5; range: 4-8) (Supplementary Table 2 and 
4).  
Regarding nutritional parameters, twelve studies reported a higher proportions of subjects with weight 
loss during follow-up period in those taking AChEI (6%; 95%CI: 4-7%, p<0.0001; I2=78%) (Table 
1). (28-30, 32-39)  There was no evidence of publication bias as shown by Kendall’s tau (-0.17; 
p=0.45) or Egger’s test (slope=-0.33±1.56; p=0.84).  
Only one study assessed weight and BMI change between baseline and follow-up reporting no 
significant variations in these 2 parameters (Table 1).(31)   
3.2.3. Randomized controlled trials reporting data on weight loss 
Nine RCTs were included in our meta-analysis reporting, among nutritional parameters, only data 
about subjects with weight loss in the treated and placebo group during follow-up.(40-48) The median 
follow-up time was 6 months (range: 2-24).  
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As reported in Supplementary Table 3, 4,311 patients with dementia treated with AChEI (5 studies: 
GAL; 2: DZP; 2: RIV) were compared to 2,699 taking placebo. The mean age was 75.1±3.9 and 
75.7±4.2 in the treated and placebo groups, respectively, and in both groups women were more 
present than men. Baseline MMSE score was 17.1±2.6 and 17.0±2.6 in the treated and placebo group, 
respectively. Data about MMSE scores at follow-up were insufficient for verifying the efficacy of 
these drugs on cognitive status assessed with this tool.  
The quality of the studies, assessed through the Jadad’s scale, was rated as good for 7 and low for 
other 2 (Supplementary Tables 3 and 5). For these studies the most common source of possible bias 
was the lack of the data about dropouts and withdrawals, as shown in Supplementary Table 5.  
As reported in Figure 1, 6% (268/4,311) in those taking AChEI and 3% (81/2,699) in those taking 
placebo reported a weight loss/decrease leading to two fold increased risk of weight loss (OR=2.18; 
95%CI: 1.50-3.17, p<0.0001; I2=29%). There was no evidence of publication bias as shown by 
Kendall’s tau (0.14; p=0.60) or Egger’s test (slope=1.35±1.01; p=0.22).  
3.3.Meta-regression analysis 
In the meta-regression analysis, we investigated if the continent in which the study was performed, 
the type of AChEI used or dementia, follow-up duration and quality of the studies could influence 
the results regarding weight loss in open-label and randomized controlled trials.  
As shown in Table 2, no moderator emerged as significant for the analyses about weight loss in open-
label trials. On the contrary, we observed an increased risk of weight loss in RCTs made in North 
America, using DZP or GAL, including only AD, and with a long follow-up period and high quality 






In this meta-analysis including 26 studies and 10,792 patients with dementia, we found that 
participants taking AChEIs experienced an increased risk of weight loss (compared to baseline in 
longitudinal and open-label trials, and vs. placebo in RCTs).  We observed no other significant 
differences in nutritional parameters were evident, but there was a paucity of studies considering other 
outcomes. Our meta-analysis from 9 RCTs demonstrates that the weight loss experienced by patients 
with dementia treated with AChEIs is double that reported in placebo.   
Clearly, our results demonstrating that AChEIs are associated with increased weight loss are a 
concern, particularly given that the medication groups are routinely prescribed around the world for 
this patient group.  To our knowledge, our meta-analysis is the first to demonstrate this relationship.   
The largest demographic group at high risk of inadequate diet and malnutrition is elderly population. 
Ageing is associated with a decline in a number of physiological functions that can impact nutritional 
status, including reduced lean body mass and a resultant decrease in basal metabolic rate, decreased 
gastric secretion and changes in the oral cavity, sensory function deficits, changes in fluid and 
electrolyte regulation.(49) Chronic comorbidities such as dementia, and medications can also 
contribute to malnutrition in these patients. The percentage of malnutrition and the risk of 
malnutrition in elderly patients, who have been newly diagnosed with dementia, were found as 11.2% 
and 42.2% in one study.(15) There are numerous studies that demonstrate a close relation between 
cognitive and functional deficits with malnutrition in patients with dementia.(1,8-10) This association 
could be attributed to the repetitive tasks and restlessness frequently occurring in these patients due 
to episodic memory, apraxia, executive planning difficulties and impaired attention and to the use of 
a large amount of energy in trying to complete the activities of daily living.(3) In addition, cognitive 
deterioration contributes to decrease oral intake by affecting daily functional status and instrumental 
activities, and chewing problems, eating difficulties due to the olfactory and taste dysfunction and 
decreased appetite might also affect food intake.(7) For these reasons, malnutrition is one of the most 
common problems in demented subjects, and this problem seems to be relevant since it is strongly 
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related with cognitive decline, progress of the disease, institutionalization, mortality, decline in 
functional status, poorer quality of life, and increase in caregiver burden.(50) 
Conversely, it has been reported that AChEIs, might improve nutritional aspects through anti-
inflammatory effects over cholinergic pathways and their improving sensation of smell and taste 
.(5,51) Moreover, improvement in swallowing function due to increased acetylcholine concentration 
by AChEIs may have an additional role in improving nutritional aspects.(52) On the contrary, these 
medications frequently cause weight loss by increasing cholinergic activity in the gastrointestinal 
system and nausea, vomiting and diarrhea.(53) Therefore, our meta-analysis sheds light on an 
important topic, within which the data was previously equivocal.   
In our meta-analysis, we found that a small proportion of people taking AChEIs experienced weight 
loss in longitudinal or open-label studies. Although these findings were significant when compared 
to baseline, they should be interpreted cautiously. First, no significant variations in mean body weight, 
BMI, or MNA values were reported. Second, the short follow-up of the studies included (median=5 
months) is far from the common clinical experience in which patients with dementia take these 
medications for years. It thus remains unclear how the long-term usage of AChEIs affects nutritional 
status, which is one of the factors that significantly influence disease progression. 
In the RCTs, we found that the percentage of those weighting loss was double in those treated with 
AChEIs compared to those treated with placebo. However, the incidences in both groups were 
relatively small (6 and 3%), particularly thinking that malnutrition and unintentional weight loss 
affect about half of the patients with dementia.(54)  Furthermore, the increased risk of weight loss 
was more evident in RCTs using DZP or GAL, with a longer follow-up period, while this was not 
observed in RCTs related to RIV.  This information might be of particular interest to the prescribing 
clinician.  However, it is noteworthy that the reason why RIV, but not DZP and GAL, is associated 
with less apparent weight loss, could also be  related to the improvement in appetite and swallowing 
over above-mentioned mechanisms by inhibiting butyrylcholinesterase as well as 
acetylcholinesterase as previously reported (15). Another reason might be that transdermal 
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rivastigmine has better tolerability and lower gastrointestinal side effects compared with oral 
formula.(55) An additional reason could be the lack of power for the studies exploring the effects of 
RIV, since only two studies investigated nutritional parameters in those taking this drug.  Nonetheless, 
future comparative studies with adequate follow up should seek to address the comparative efficacy 
and side effects of these differing medication classes with a particular emphasis on monitoring weight. 
Clinically, considering our results, it is important that prescribing clinicians carefully consider the 
risk and benefit ratio of each different medication.  Routine monitoring of nutritional status, in 
particular weight, should form part of good clinical practice in patients with dementia treated with 
these medication.   
Although our meta-analysis is the first exploring the effects of AChEIs on nutritional parameters and 
included a large number of studies and participants, there are some limitations that should be 
mentioned. The main limitation is that very few information exists in nutritional parameters other 
than weight loss were available.  More research using multidimensional parameters and parameters 
exploring protein malnutrition is needed. Second, the effects of AChEIs on different types of 
dementia were not evaluated because of limited number of patients with non-Alzheimer dementia. 
However, in several countries, the use of AChEIs is not licensed for AD. Third, the definition of 
weight loss differed across studies and there was limited information on the magnitude of weight loss. 
Fourth, we were not able to distinguish the effect of oral vs. patch formulations of AChEIs, but it 
could be of importance since patches could have less nutritional side effects. Fifth, we were not able 
to verify if the use of these medications was followed by a real improvement in cognitive function 
probably necessary to improve nutritional status. A last limitation is the short follow-up of the studies 
included. 
5. CONCLUSION 
The treatment with AChEIs is associated with a significant risk of weight loss in patients with 
dementia in the elderly. Data from 9 RCTs found people taking AChEIs are two times more likely to 
experience weight loss than in the placebo.  In light of our findings, when prescribing AChEIs, people 
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in clinical practice should routinely monitor nutritional status in patients with dementia. Further 
studies with adequate follow up are required, comparing the relative risk and benefit ration of 
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Table 1. Meta-analysis of longitudinal studies and open-label trials findings about nutritional parameters. 
Notes: aEvent rate;b: standardized mean difference. Abbreviations: BMI: Body mass index., MNA: Mini Nutritional Assessment 
Type of study 







Weight loss (compared to baseline) 
Longitudinal 2 604 0.05 (0.01-0.34)a Tau² = 2.53; Chi² = 24.0, df = 1 (P<0.0001); I² = 95 % 
Open-label 12 5640 0.06 (0.04-0.07)a Tau² = 0.18; Chi² = 51.9, df = 11 (P<0.0001); I² = 78 % 
Weight change (compared to baseline) 
Longitudinal 3 676 0.01 (-0.13; 0.15)b Tau² = 0.00; Chi² = 2.49, df = 2 (P=0.29); I² = 20 % 
Open-label 1 90 0.06 (-0.24; 0.35) b - 
BMI change (compared to baseline) 
Longitudinal 2 147 0.15 (-0.33; 0.63) b Tau² = 0.08; Chi² = 2.97, df = 1 (P=0.09); I² = 66% 
Open-label 1 90 
0.21 (-0.08; 0.50) 
b 
- 
MNA change (compared to baseline) 
Longitudinal 1 116 0.08 (-0.17; 0.34) b - 
Open-label No studies available  
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Figure 1. Odds ratio for weight loss in acetilcholinesterasic inhibitors (AChEI) group vs. 








Table 2. Strata for odds ratios for weight loss in randomized controlled (RCTs) and open-label 
trials. 
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a P-value for the interaction across strata.  
bFollow-up: for RCTs short follow-up was defined as studies with a mean follow-up period <5 
months; long as RCTs with a follow-up period  >5 months. 
cQuality: for open-label studies, low quality was defined as eNOS<5 and high>5;  for RCTs low 
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P-value 
a 
0.05 (0.04-0.07) 
<0.0001 
78% (<0.0001) 
8 
 
0.07 (0.05-0.10) 
<0.0001 
50% (0.11) 
4 
 
0.23 
2.37 (0.41-
13.89) 
0.34 
75% (0.05) 
2 
 
2.09 (1.45-3.00) 
<0.0001 
27% (0.22) 
7 
 
0.89 
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